Phase 2 trial of RGX-314 in diabetic retinopathy underway

The first patient has been dosed in a phase 2 trial evaluating the efficacy, safety and tolerability of suprachoroidal delivery of RGX-314 for the treatment of diabetic retinopathy, according to a Regenxbio press release.
ALTITUDE is a multicenter, open-label, randomized, controlled dose-escalation trial expected to enroll approximately 40 patients with diabetic retinopathy (DR). Patients will receive either RGX-314 via the SCS microinjector or observational control at a 3:1 ratio. Two doses levels of RGX-314, 2.5 × 1011 GC per eye and 5 × 1011 GC per eye, will be evaluated.
(Read more...)

Full Story →